echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ESMO Flash Report: How to choose newly-treated EGFR-mutant non-squamous NSCLC patients?

    ESMO Flash Report: How to choose newly-treated EGFR-mutant non-squamous NSCLC patients?

    • Last Update: 2021-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Editor's note: l Adding atezolizumab to the FOLFOXIRI/bevacizumab regimen can prolong the progression-free survival of patients with metastatic colorectal cancer——LBA20—FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as fifirst-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO.
    l For newly-treated EGFR-mutant non-squamous NSCLC patients, osimertinib is better than a single agent or a combination of benzal Valizumab is good? ——LBA44—primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study.
    l How to optimize the ToGA program? Trastuzumab+nivolumab+FOLFOX further improves the overall survival rate of patients with esophageal gastric adenocarcinoma! ——LBA45—Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) – results of the randomized phase 2 INTEGA trial (AIO STO 0217).
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.